L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus

Eur J Neurosci. 2006 May;23(9):2395-403. doi: 10.1111/j.1460-9568.2006.04758.x.

Abstract

Levodopa (L-DOPA), the metabolic precursor of dopamine, is widely used as a pharmacological agent for the symptomatic treatment of Parkinson's disease. However, long-term L-DOPA use results in abnormal involuntary movements such as dyskinesias. There is evidence that abnormal cell signaling in the basal ganglia is involved in L-DOPA-induced dyskinesia. The subthalamic nucleus (STN) plays a key role in the circuitry of the basal ganglia and in the pathophysiology of Parkinson's disease. However, the contribution of the STN to L-DOPA-induced dyskinesias remains unclear. The objective of this work was to study the effects of acute or chronic systemic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of dopamine neurons on c-fos expression in the STN and test the hypothesis that these effects correlate with L-DOPA-induced dyskinesias. c-fos mRNA expression was measured in the STN by in situ hybridization histochemistry at the single cell level. Our results confirm earlier evidence that the chronic administration of L-DOPA to rats with a unilateral 6-OHDA lesion increases c-fos expression in the STN. We also report that c-fos expression can be increased following an acute injection of L-DOPA to 6-OHDA-lesioned rats but not following a chronic injection of L-DOPA to sham-operated, unlesioned rats. Finally, we provide evidence that the occurrence and severity of dyskinesia is correlated with c-fos mRNA levels in the ipsilateral STN. These results suggest that altered cell signaling in the STN is involved in some of the behavioral effects induced by systemic L-DOPA administration.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Autoradiography / methods
  • Behavior, Animal
  • Dopamine / metabolism*
  • Dopamine Agents / adverse effects*
  • Dopamine Uptake Inhibitors / pharmacokinetics
  • Dyskinesias / etiology*
  • Dyskinesias / metabolism
  • Dyskinesias / physiopathology
  • Functional Laterality
  • Gene Expression / drug effects
  • Immunohistochemistry / methods
  • In Situ Hybridization / methods
  • Levodopa / adverse effects*
  • Male
  • Mazindol / pharmacokinetics
  • Neurons / drug effects*
  • Oxidopamine / toxicity
  • Proto-Oncogene Proteins c-fos / genetics
  • Proto-Oncogene Proteins c-fos / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Substantia Nigra / injuries
  • Subthalamic Nucleus / cytology*
  • Subthalamic Nucleus / drug effects
  • Time Factors
  • Tritium / pharmacokinetics

Substances

  • Dopamine Agents
  • Dopamine Uptake Inhibitors
  • Proto-Oncogene Proteins c-fos
  • Tritium
  • Levodopa
  • Oxidopamine
  • Mazindol
  • Dopamine